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Abstract
Background: We sought to define a cutoff for β-amyloid 1–42 in cerebrospinal fluid (CSF), a key marker for
Alzheimer’s disease (AD), with data-driven Gaussian mixture modeling in a memory clinic population.
Methods: We performed a combined cross-sectional and prospective cohort study. We selected 2462 subjects with
subjective cognitive decline, mild cognitive impairment, AD-type dementia, and dementia other than AD from the
Amsterdam Dementia Cohort. We defined CSF β-amyloid 1–42 cutoffs by data-driven Gaussian mixture modeling in
the total population and in subgroups based on clinical diagnosis, age, and apolipoprotein E (APOE) genotype.
We investigated whether abnormal β-amyloid 1–42 as defined by the data-driven cutoff could better predict
progression to AD-type dementia than abnormal β-amyloid 1–42 defined by a clinical diagnosis-based cutoff using
Cox proportional hazards regression.
Results: In the total group of patients, we found a cutoff for abnormal CSF β-amyloid 1–42 of 680 pg/ml (95% CI
660–705 pg/ml). Similar cutoffs were found within diagnostic and APOE genotype subgroups. The cutoff was
higher in elderly subjects than in younger subjects. The data-driven cutoff was higher than our clinical diagnosis-
based cutoff and had a better predictive accuracy for progression to AD-type dementia in nondemented subjects
(HR 7.6 versus 5.2, p < 0.01).
Conclusions: Mixture modeling is a robust method to determine cutoffs for CSF β-amyloid 1–42. It might better
capture biological changes that are related to AD than cutoffs based on clinical diagnosis.
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Background
Decreased β-amyloid 1–42 (Aβ42) in cerebrospinal fluid
(CSF) is indicative of Alzheimer’s disease (AD) pathology
and part of research criteria for AD [1–4]. However,
there is no universal cutoff value to define abnormal
CSF Aβ42. This is in part due to the variability of Aβ42
measurements across laboratories [5, 6]. In addition,
clinical centers have used different methods to define a
cutoff [7]. Often, a cutoff value is determined by com-
paring CSF Aβ42 levels of cognitively normal subjects
with those of patients with a clinical diagnosis of AD-
type dementia. However, about 10% of the subjects with
clinical AD-type dementia do not have amyloid path-
ology [8], and 25% of subjects with normal cognition
can have amyloid pathology [9], which biases the cutoff
value. Data-driven Gaussian mixture modeling provides
an alternative approach that does not rely on clinical
diagnosis [10]. With this approach, CSF Aβ42 levels
showed a bimodal distribution representing a normal
and an abnormal population. However, it is unclear
whether this method is influenced by clinical diagnosis
and risk factors for AD.
We aimed to define a cutoff for CSF Aβ42 with mix-
ture modeling and to investigate whether this cutoff was
dependent on clinical diagnosis, age, and apolipoprotein
E (APOE) genotype. We compared the diagnostic accur-
acy and the predictive accuracy for AD-type dementia
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progression of the new cutoff value with our previous
clinically based cutoff [11]. We also performed a simula-
tion analysis to determine the minimum sample size




We selected 2462 subjects from the Amsterdam Demen-
tia Cohort (ADC) [12] with subjective cognitive decline
(SCD; n = 448), mild cognitive impairment (MCI; n =
490), AD dementia (n = 1031), and dementia other than
AD (n = 493) who had CSF measurements available at
the time of their first visit at the memory clinic between
August 1997 and July 2015. All patients underwent
standardized dementia screening at baseline, including
physical and neurological examinations, electroenceph-
alograms, magnetic resonance imaging, and laboratory
tests. Cognitive screening included the Mini Mental
State Examination and, in over 90% of the subjects, a
comprehensive neuropsychological test battery. Diagno-
ses were made by consensus among a multidisciplinary
team that did not have knowledge of the CSF results,
and they were based on the following clinical criteria.
Subjects were diagnosed with SCD when cognitive
complaints were present but criteria for MCI,
dementia, or any other neurological or psychiatric dis-
orders were not met and all other examinations were
normal [13]. Subjects were diagnosed with MCI ac-
cording to the established MCI criteria [14]. Subjects
with AD-type dementia were diagnosed according to
the criteria of the National Institute of Neurological
and Communicative Disorders and Stroke-Alzheimer’s
Disease and Related Disorders Association [4, 15]. Sub-
jects with non-AD-type dementia included subjects
with behavioral variants of frontotemporal dementia
(n = 204) [16, 17], dementia with Lewy bodies (n = 113)
[18], vascular dementia (n = 66) [19], corticobasal degener-
ation or syndrome (n = 31 or n = 10, respectively) [20],
progressive supranuclear palsy (n = 44) [21], alcohol-
related dementia (n = 3), Huntington’s disease (n = 3),
Parkinson’s disease (n = 1), normal pressure hydroceph-
alus (n = 3), CADASIL (cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoence-
phalopathy; n = 1), Creutzfeldt-Jakob disease (n = 3),
tauopathy (n = 2), and dementia without a known cause
(n = 9). All subjects gave written informed consent for
the use of their clinical and biomarker data for research
purposes, and the ethical review board of the VU
University Medical Center approved the study.
Follow-up assessment
Subjects were followed according to clinical needs. The
standard follow-up procedure included a 6-month
follow-up examination for subjects with dementia and a
12-month follow-up visit for subjects without dementia
[12]. Neuropsychological tests were repeated every
12 months. Diagnoses at follow-up were made on the
basis of clinical criteria listed above by consensus among
a multidisciplinary team.
CSF Aβ1–42 analyses
CSF was collected from 67% of the subjects in the ADC
[12]. Reasons for not collecting CSF were refusal, contra-
indications, technical failure, or CSF having been col-
lected elsewhere. CSF was obtained by lumbar puncture
using a 25-gauge needle with a syringe into 10-ml poly-
propylene tubes (Sarstedt, Nümbrecht, Germany).
Within 2 h, CSF samples were centrifuged at 1800 × g
for 10 minutes at 4 °C. The CSF supernatant was trans-
ferred to new polypropylene tubes and stored at −20 °C
until further analysis (within 2 months). Baseline Aβ1–42
was measured using a commercially available enzyme-
linked immunosorbent assay (Innotest β-amyloid(1-42;
Innogenetics, Ghent, Belgium) on a routine basis as de-
scribed before [11]. The intra-assay coefficient of vari-
ation (mean ± SD) for Aβ1–42 was 2.0 ± 0.5%, calculated
by averaging the coefficient of variation of duplicates
from five runs randomly selected over 2 years. The
inter-assay coefficient of variation (mean ± SD) was 10.9
± 1.8%, as analyzed in a high and low pool from 13 con-
secutive pool preparations used in total in 189 runs. The
team performing the CSF analysis was unaware of the
clinical diagnoses.
Statistical analyses
Baseline characteristics were compared between diag-
nostic groups with analysis of variance and Kruskal-
Wallis or chi-square tests, where appropriate, using IBM
SPSS Statistics version 20.0 software (IBM, Armonk, NY,
USA). A difference with a p value less than 0.05 was
considered significant. Gaussian mixture modeling was
used to define a cutoff for abnormal CSF Aβ42 using the
R statistical software program version 3.2.1 mixtools
package. First, the number of distributions that best de-
scribed the data was determined with the R boot.comp
function. Next, we defined a data-driven cutoff as the
point where the lines of two fitted normal distributions
crossed each other. The main analyses included all sub-
jects. We repeated mixture modeling in subgroups based
on diagnosis, age (dichotomized based on the median
age of 66.5 years), and APOE ε4 allele carriership. Boot-
strap sampling was used to determine 95% CIs of the
cutoff. Cutoffs were considered to be statistically differ-
ent between subgroups when their 95% CIs did not
overlap.
New cutoff values were compared with our previously
clinically defined cutoff of 550 pg/ml, which was based
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on subjects seen between 2001 and 2007 (n = 1070) [11].
For this comparison, we repeated mixture modeling in a
subset of data including subjects from this time period.
Using this subset, we further tested differences between
the clinical and new cutoff values in discrimination be-
tween nondemented subjects with or without AD-type
dementia at follow-up. In addition, using Cox propor-
tional hazard models, we compared the association of
the old cutoff and new cutoff with time to AD-type de-
mentia progression, including age and sex as covariates.
For these analyses, nondemented patients were included
when they had at least 6 months of follow-up available.
We compared both models with chi-square tests of the
log-likelihood ratio. A difference with a p value less than
0.05 was considered significant. Statistical analyses for
multivariate Cox regression were performed using R ver-
sion 3.2.3 software.
Finally, we studied the minimum number of subjects
per clinical population necessary to reliably estimate the
cutoff in a data-driven way. To this end, we simulated
CSF Aβ42 values from a bimodal distribution with mean
and SD values as estimated from our dataset. We recal-
culated the cutoffs and 95% CIs for sample sizes with
varying numbers starting from n = 300 to 3000 with
steps of 100. The minimum sample size required to ob-
tain a reliable cutoff was determined as the sample size
for which 95% CI lines were larger than the mean cutoff
±10%, which is currently used as a rule-of-thumb indica-
tion of acceptable variability in CSF Aβ42 levels.
Results
Baseline characteristics
Table 1 shows the baseline characteristics according to
diagnostic group. Briefly, patients with AD and patients
with MCI were older and included a higher percentage
of APOE ε4 allele carriers than the other groups. CSF
Aβ42 levels were highest for SCD, followed by non-AD-
type dementia, MCI, and AD-type dementia. Of the
nondemented subjects, over an average follow-up period
of 3.2 (SD 2.04) years, 21 (9%) of the subjects with SCD
progressed to MCI and 13 (5%) to AD-type dementia,
and 146 (39%) of the subjects with MCI progressed to
AD-type dementia.
CSF Aβ1–42 cutoff based on mixture modeling
In the total sample and all subgroups, a bimodal distri-
bution best fitted the data (Table 2). In the total sample,
this yielded a cutoff of 680 pg/ml (95% CI 660–705 pg/
ml) (Fig. 1a). With this cutoff, 55% of our population fell
into the abnormal amyloid distribution. Similar cutoffs
were found when we repeated mixture modeling within
the dementia group (694 pg/ml, 95% CI 670–721 pg/
ml), the pooled sample of subjects with SCD and MCI
(664 pg/ml [95% CI 621-712 pg/ml), subjects with SCD
(621 pg/ml (95% CI 526-901 pg/ml) and subjects with
MCI (696 pg/ml [95% CI 654-758 pg/ml) (Fig. 1b–e). A
lower cutoff was found for subjects younger than
66.5 years (645 pg/ml [95% CI 617-678 pg/ml) than sub-
jects older than 66.5 years (723 pg/ml [95% CI 691-
762 pg/ml) (Fig. 1f and g). The cutoff for CSF Aβ42 was
higher in APOE ε4 carriers than in noncarriers (resp.
716 pg/ml [95% CI 684-756 pg/ml; 650 pg/ml [95% CI
611-689 pg/ml), but this did not reach statistical signifi-
cance (Fig. 1h and i).
Comparison with previously defined cutoff
The cutoff of 680 pg/ml based on mixture modeling was
substantially higher than our previously clinically defined
cutoff of 550 pg/ml (95% CI 531–570 pg/ml) [11]. Re-
peated mixture modeling in the subset of subjects with











Age, years 66.8 (7.0) 64.4 (6.2)b,c,d 68.2 (6.9)a,c,d 67.3 (7.2)a,b 66.9 (6.8)a,b
Female sex, n (%) 1049 (43) 170 (38)c 181 (37)c 528 (51)a,b,d 170 (34)c
Years of education 11.1 (3.0) 11.9 (3.1)b,c,d 11.4 (3.2)a,c,d 10.8 (2.8)a,b 10.5 (2.9)a,b
MMSE score 23.6 (5.2) 28.3 (1.7)b,c,d 26.5 (2.5)a,c,d 20.4 (5.0)a,b,d 23.0 (5.2)a,b,c,
APOE ε4 allele carriers, n (%) 1186 (54) 158 (35)b,c 242 (49)a,c,d 615 (60)a,b,d 171 (35)b,c
CSF Aβ1–42, pg/ml 667 (289) 906 (277)b,c,d 676 (295)a,c,d 504 (174)a,b,d 781 (278)a,b,c
CSF tau, pg/ml 527 (401) 317 (205)b,c,d 486 (313)a,c,d 705 (406)a,b,d 394 (443)a,b,c
CSF p-tau, pg/ml 70 (37) 52 (25)b,c 70 (35)a,c,d 88 (39)a,b,d 50 (25)b,c
Outcome at follow-up AD-type/no
AD-type dementia (% AD-type dementia)
– 13/235 (5) 146/224 (61) – –
Average follow-up duration, years – 2.93 (1.99) 2.41 (1.46) – –
Data are mean (SD), unless otherwise specified. Superscript letters indicate that this group shows a statistically significant difference (p < .05) with other groups as
labelled with a,b,c,d or e in the column headers
Abbreviations: SCD Subjective cognitive decline, MCI Mild cognitive impairment, AD Alzheimer’s Disease, APOE Apolipoprotein E, CSF Cerebrospinal fluid, Aβ1–42
β-Amyloid 1–42, - Not applicable
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CSF analysis in the 2001–2007 period (in which subjects
were selected for the clinically based cutoff calculation)
also resulted in a higher cutoff (615 pg/ml, 95% CI 573–
673 pg/ml) (Fig. 2) than the clinically defined cutoff.
In this subset, using a cutoff value of 615 pg/ml, 439
subjects were classified as having abnormal amyloid,
which was a 13% increase compared with the 390 sub-
jects classified by the clinically defined cutoff. The sensi-
tivity of the cutoff of 615 pg/ml for AD-type dementia
was 0.89 with a specificity of 0.62. The clinically defined
cutoff of 550 pg/ml resulted in a sensitivity of 0.86 with
a specificity of 0.65. Of the nondemented subjects who
later progressed to AD-type dementia, 87% had CSF
Aβ42 levels less than 615 pg/ml, compared with 76%
with CSF Aβ42 levels less than 550 pg/ml. For nonde-
mented subjects who did not progress to AD-type
dementia, these proportions were 30% versus 21%, re-
spectively (Table 3). Survival analyses showed that both
cutoffs were predictive of the time to development of
AD-type dementia (550 pg/ml cutoff HR = 5.14, 95% CI
2.96–8.93; pg/ml; versus 615 pg/ml cutoff HR 7.44, 95%
CI 3.74–14.79) (Table 4). The HR for the development
of AD-type dementia was significantly greater for the
new cutoff of 615 pg/ml than for the cutoff of 550 pg/ml
(p < 0.001).
We further explored why the data-driven cutpoint
was somewhat lower in the subset of subjects with CSF
analysis in the 2001–2007 period than in the total sam-
ple. Additional file 1: Figure S1 shows that the peaks of
CSF Aβ42 level distributions seem to shift over subse-
quent years. This could not be explained by a difference
in patient population, because the distribution of diag-
noses remained comparable over time (χ2 (45) = 61.32,
p > 0.05) (Additional file 1: Table S1). We further explored
whether this shift was due to an assay drift, and we re-
peated all subgroup analyses stratified for the time period
when the lumbar puncture was obtained (2001–2007 ver-
sus 2008–2015) (see Additional file 1: Table S2 for baseline
characteristics). Briefly, the cutpoint in the total group
was higher in the 2008–2015 subsample (697 pg/ml
[675–723 pg/ml]) than in the 2001–2007 subsample
(615 pg/ml [573–673 pg/ml]) (Additional file 1: Table S3
and Figure S2 and S3). Subgroup analyses showed that the
cutpoint for the dementia group and for APOE ε4 allele
carriers was also higher in the 2008–2015 group than in
the 2001–2007 group. Cutpoints for other subgroups did
not differ between time periods.
Minimum sample size required
Additional file 1: Figure S4 shows the mean and SD
values for different sample sizes, varying from 300 to
3000 subjects with steps of 100. The average CSF Aβ42
cutoff was 679 pg/ml and remained similar with increas-
ing sample size, whereas the 95% CI became narrower.
Accepting a maximum deviation from the cutoff of
±10%, a minimum sample size of 800 is required for an
acceptable 95% CI of 637–744 pg/ml. Our determined
cutoff of 680 pg/ml and 95% CI fell within this range.
Discussion
Using a data-driven Gaussian mixture modeling ap-
proach, we determined a cutoff of 680 pg/ml for abnor-
mal CSF Aβ42 levels. This cutoff was independent of the
cognitive stage and APOE genotype. The cutoff was
higher in older than in younger subjects. With this new
cutoff, a good classification of subjects with underlying
AD pathology was achieved because 88% of nondemen-
ted subjects who later developed AD-type dementia had
CSF Aβ42 levels below our new cutoff. Our results sug-
gest that mixture modeling is a robust method to deter-
mine cutoff values for CSF Aβ42.
In the total sample, we found that subjects with AD-
related characteristics (dementia, MCI, older age, and
APOE ε4 carriers) fell mainly within the abnormal amyl-
oid distribution and that subjects without AD-related
characteristics (SCD, younger age, and APOE ε4
Table 2 Fit statistics from bootstrap to test the null hypothesis of a K-component fit versus (K + 1)-component fit for total sample
Log-likelihood 1 versus 2 components Log-likelihood 2 versus 3 components
Observed Bootstrap (95% CI) p Value Observed Bootstrap (95% CI) p Value
All subjects 653.98 6.51 (1.65–15.69) <0.001 2.16 16.67 (0.78–11.15) 0.77
Subjective cognitive decline 15.64 6.12 (1.72–13.25) 0.03 2.45 5.8 (0.94–17) 0.74
Mild cognitive impairment 124.50 5.79 (1.91–12.63) <0.001 9.95 5.55 (0.54–10.82) 0.08
Nondemented 132.93 6.44 (1.5–13.1) <0.001 10.41 4.34 (0.73–11.3) 0.07
Dementia 471.81 6.01 (1.49–13.21) <0.001 3.61 4.34 (0.53–9.56) 0.55
Younger than 66.5 years old 261.16 5.86 (1.4–12.82) <0.001 2.02 4.64 (0.65–9.83) 0.79
Older than 66.5 years old 397.49 6.42 (1.82–14.46) <0.001 9.39 4.82 (0.68–11.64) 0.11
APOE ε4 noncarrier 138.75 6 (1.77–13.01) <0.001 4.19 6.91 (0.79–11.26) 0.41
APOE ε4 carrier 367.29 5.83 (1.89–11.50) <0.001 10.49 7.25 (0.6–11.79) 0.07
APOE Apolipoprotein E
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noncarriers) fell mainly within the normal amyloid dis-
tribution. This supports the idea that a bimodal distribu-
tion of amyloid levels represents normal and abnormal
distributions of amyloid. When comparing cutoffs based
on age and APOE ε4 groups, the data-driven cutoff was
higher in older than in younger subjects and tended to
be higher in APOE ε4 allele carriers than in noncarriers.
One explanation for the higher cutoff in these groups is
that it reflects a difference in amyloid processing. How-
ever, this is unlikely, because a previous study showed
that CSF Aβ42 levels were not dependent on APOE ε4
genotype after correction for Aβ deposition as measured
by amyloid positron emission tomography (PET) [22].
Furthermore, researchers in another study found a simi-
lar cutoff for CSF Aβ42 across age groups [23]. A more
likely explanation for the higher cutoff is that, within the
old and APOE ε4 groups, relatively few subjects had
normal CSF Aβ42 levels. As a consequence, the distribu-
tion of values reflecting normal Aβ42 levels was relatively
wide, which resulted in a shift to a higher cutoff that
separated the abnormal and normal CSF Aβ42 distribu-
tion. Thus, the variability in cutoffs is more likely to re-
sult from different sampling frequencies of normal and
abnormal Aβ42 populations rather than from differences
in amyloid processing. This suggests that, in order to de-
termine a cutoff with this data-driven approach, the data
need to contain a sufficient sample from both the nor-
mal and abnormal populations. For example, for the
SCD group, which had few subjects who had abnormal
CSF Aβ42, the 95% CI was wide, so the resulting cut-
point should be considered with caution.
The cutoff of 680 pg/ml defined by Gaussian mixture
modeling is higher than our previous clinically defined
cutoff of 550 pg/ml. This indicates that clinically based
cutoffs may underestimate the presence of abnormal
CSF Aβ42. Still, the difference in cutoffs may also have
resulted from drift in CSF Aβ42 levels over time, owing
Fig. 1 Cerebrospinal fluid β-amyloid 1–42 (Aβ42) cutoff values based
on mixture modeling. a Total sample. b Demented subjects. c Non-
demented subjects. d Subjects with subjective cognitive decline
(SCD). e Subjects with mild cognitive impairment (MCI). f Subjects
≤66.5 years old. g Subjects >66.5 years old. h Apolipoprotein E
(APOE) ε4 allele noncarriers. i APOE ε4 allele carriers. Subjects with a
clinical diagnosis of Alzheimer’s disease (AD)-type dementia at
baseline or at follow-up (nondemented subjects) are shown in gray
Fig. 2 Cerebrospinal fluid β-amyloid 1–42 (Aβ42) cutoff values based
on mixture modeling in subjects seen between 2001 and 2007. Sub-
jects with a clinical diagnosis of Alzheimer’s disease (AD)-type de-
mentia at baseline or at follow-up are shown in gray
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to variability in batches used for the biomarker analysis
[6]. To test this possibility, we repeated our analyses
based on data obtained in a time period similar to the
previously clinically defined cutoff (2001–2007). Indeed,
the cutpoint in the 2001–2007 subsample (615 pg/ml)
was lower than that in the 2007–2015 subsample
(697 pg/ml). Nevertheless, the data-driven cutoff derived
for the 2007–2015 subsample was still higher than the
clinically defined cutoff of 550 pg/ml, suggesting that
our higher cutoff value was not due simply to a change
in assay performance over time.
Our data-driven cutoff is within the same range as the
CSF Aβ42 cutoff that shows the best concordance with
amyloid PET (640 pg/ml) in our cohort [24] and in other
cohorts (616–647 pg/ml) in which CSF Aβ42 was
assessed with the Innotest assay [25–27]. This similarity
between the amyloid PET derived cutoff for CSF Aβ42
and our new cutoff suggests that Gaussian mixture mod-
eling is better able than a cutoff based on clinical diag-
nosis to capture and differentiate subjects from a
memory clinic sample in terms of amyloid pathology.
The higher cutoff led to an increased sensitivity to de-
tect subjects with AD-type dementia at baseline and an
increased sensitivity to predict future AD-type dementia
in subjects with SCD or MCI. This increase in sensitivity
could at least in part explain the results of a recent study
that demonstrated an increased risk for cognitive decline
in subjects with low normal CSF Aβ42 values, based on a
classical clinically defined cutoff [28]. However, subjects
with a non-AD type dementia and subjects with SCD
and MCI who did not convert to AD-type dementia also
more often had abnormal CSF Aβ42 with the new cutoff.
Some of these subjects may have low normal scores, but
it could also mean that amyloid positivity is typically
underestimated in these populations. For example, it is
possible that some of the subjects with SCD and MCI
might have developed AD-type dementia after the period
in which they were followed.
A strength of our study is the availability of a large,
clinically well-characterized cohort with longitudinal
data. This made it possible to analyze cutoffs for CSF
Aβ42 for different subgroups of patients and to assess
the ability of the new cutoff to detect future AD-type de-
mentia before cognitive impairment becomes evident. A
limitation of the Cox regression analysis was that the
time to dementia was an approximation because the
event occurred at an unknown time between two visits.
The best gold standard currently available to measure
amyloid pathology in vivo is amyloid PET because this
correlates strongly with amyloid status determined post-
mortem [29]. The similarity in cutoffs between our ap-
proach and amyloid PET indicates that centers that do
not have PET techniques available can improve the ac-
curacy of detecting abnormal amyloid with mixture
modeling. A possible limitation of the method, however,
is that the sample used for the cutoff definition should
contain a sufficient number of subjects with normal and
abnormal amyloid. We found that at least 800 subjects
are needed to obtain a sufficiently reliable cutoff for CSF
Aβ42. This number was calculated under the assumption
that, in a memory clinic (as in ours), 55% of patients
have abnormal CSF Aβ42 levels and 45% have normal
levels. However, these distribution parameters might not
apply to all memory clinics, because they are dependent
Table 3 Number of subjects of subsample between 2001 and 2007 according to diagnosis at baseline, outcome at follow-up, and
cerebrospinal fluid β-amyloid 1–42 cutoff score
Total group (n = 688) CSF Aβ42 cutoff <550 pg/ml CSF Aβ 42 cutoff <615 pg/ml
AD-type dementia, n (%) 288 (42) 236 (82) 255 (89)
Non-AD-type dementia, n (%) 143 (21) 49 (34) 55 (38)
SCD with follow-up available
Converted to AD-type dementia, n (%) 7 (7) 5 (71) 6 (86)
Not converted to AD-type dementia, n (%) 91 (93) 16 (18) 20 (22)
MCI with follow-up available
Converted to AD-type dementia, n (%) 69 (53) 53 (77) 60 (87)
Not converted to AD-type dementia, n (%) 60 (47) 16 (27) 26 (43)
Data are from the subsample of patients seen between 2001 and 2007. For this time period, the cutoff for CSF Aβ 42 determined with Gaussian mixture modeling
was 615 pg/ml
Abbreviations: CSF Cerebrospinal fluid, Aβ 42 Amyloid-β 1–42, SCD Subjective cognitive decline, MCI Mild cognitive impairment, AD Alzheimer’s disease
Table 4 Cox proportional HRs (95% CIs) for clinical progression
to Alzheimer’s disease-type dementia in nondemented subjects
CSF Aβ42 cutoff HR (95% CI) Log-likelihood ratio χ2
<550 pg/ml 5.14 (2.96–8.93)a −327.85 n.a.
<615 pg/ml 7.44 (3.74–14.79)a −324.66 6.38b
Analyses were adjusted for age and sex. Data are from the subsample of
nondemented sample with at least 6 months follow-up available seen be-
tween 2001 and 2007. The event rate was 33%, and about 13% of subjects
were lost to follow up per year
Abbreviations: CSF Cerebrospinal fluid, Aβ42 β-Amyloid 1–42, n.a. Not applicable
ap = 0.0001
bDecrease in χ2 p < 0.01
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on the type of patients seen and their age. For example,
if 60% of patients in a population had abnormal CSF
Aβ42 levels and 40% had normal CSF Aβ42 levels, a sam-
ple size of at least 450 subjects would be needed to de-
termine a reliable cutoff (data not shown).
Conclusions
Using a data-driven mixture method, we found a new
cutoff for abnormal CSF Aβ42 levels that was higher and
was better able to predict future AD-type dementia than
our clinically determined cutoff. The increase in cutoff
for CSF Aβ42 has implications for clinical practice be-
cause more patients will be labeled as having AD path-
ology than were so labeled using the old cutoff. This is
likely to impact communication with and management
of patients [30]. Still, regardless of the cutoff used at this
time, the decision whether to communicate abnormal
Aβ42 values with patients will be challenging because no
therapy is yet available. Disclosure of pathological diag-
nosis will probably depend on the AD stage, the wish of
patients to know, and the view of the clinician regarding
this topic [31].
Additional file
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